MEDIA STATEMENT

Singapore, 24 September 2026 - Northern TK Venture Pte Ltd (NTK), an indirect wholly owned subsidiary of IHH Healthcare, has filed a petition for appeal with the Tokyo High Court against the judgment issued by the Tokyo District Court on 10 September 2026. [https://ihhmy.listedcompany.com/newsroom/IHH_Announcement_Material_Litigation_10.09.2026_20260910.pdf]

Having assessed the judgment, NTK concluded that it warrants appellate review by a higher court, and has accordingly exercised its right of appeal.

IHH's position is that it has suffered losses arising from delays in obtaining the mandatory tender offer approvals required for its acquisition of Fortis Healthcare. These delays occurred in the context of a dispute between Daiichi Sankyo and certain judgment debtors, to which IHH was not a party.

IHH-NTK's acquisition of Fortis in 2018 was undertaken through a transparent, widely public and fully regulated process. The transaction obtained all necessary corporate, shareholder and regulatory approvals, including those required under the Competition Commission of India (CCI) and SEBI takeover regulations.

As one of the largest and longest-standing foreign direct investors in India's hospital sector, IHH has remained steadfast in its commitment to the country despite the challenges arising from this matter. We take pride in our contribution to the advancement of healthcare in India through sustained investment, responsible stewardship, and a strong commitment to patient care and governance excellence.

India remains a key strategic market for IHH, and we are committed to deepening our presence and increasing our investments in the country. Over the next three to five years, we plan to increase our stake in Fortis to 51%, further integrate our Fortis and Gleneagles platforms, and expand our capacity to approximately 10,000 beds by 2031 to meet India's growing healthcare needs.

ABOUT IHH HEALTHCARE ("IHH")

IHH is a leading multinational healthcare provider shaping the future of care. Driven by our aspiration to Care. For Good., we unite medical excellence and innovation, pushing boundaries through our trusted brands such as Acibadem, Gleneagles, Fortis, Island, Mount Elizabeth, Pantai, Parkway and Prince Court.

Across 10 countries, including Malaysia, Singapore, Türkiye, India and Greater China, our 76,000-strong team delivers world-class excellence every day, within and beyond our 190 healthcare facilities, including 89 hospitals. Our comprehensive services span the full healthcare continuum, from primary and ambulatory to quaternary care, complemented by diagnostics, imaging, rehabilitation, telehealth and home care.

In partnership with our stakeholders, IHH is advancing value-based care, building a sustainable healthcare ecosystem and creating meaningful impact, as we work towards our vision to become the world's most trusted healthcare services network.
www.ihhhealthcare.com

For more information or to speak to an IHH spokesperson, please contact:

Lim Bee Ling
Group Communications & Branding
IHH Healthcare
t. +65 97650598
e. beeling.lim@ihhhealthcare.com

Denise Selva
Mutant Communications on behalf IHH Healthcare
t. +60-17 494 0557
e. deenesha@mutant.com.my